TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Clover Biopharmaceuticals Ltd. ( (HK:2197) ).
Clover Biopharmaceuticals Ltd. has initiated a Phase I clinical trial for its new respiratory combination vaccine candidates, SCB-1022 and SCB-1033, which target RSV, hMPV, and PIV3. This trial follows promising results from a previous study comparing Clover’s RSV PreF vaccine candidate to GSK’s AREXVY, indicating a strong immunogenicity and tolerability profile. The ongoing trial will enroll up to 192 older adults to assess the safety, reactogenicity, and immunogenicity of these new vaccine candidates, potentially strengthening Clover’s position in the vaccine market.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on the development of innovative vaccines. The company utilizes its proprietary Trimer-Tag vaccine technology platform to create subunit vaccine antigens, targeting respiratory diseases such as RSV, hMPV, and PIV3.
Average Trading Volume: 1,448,367
Technical Sentiment Signal: Hold
Current Market Cap: HK$337.2M
For an in-depth examination of 2197 stock, go to TipRanks’ Overview page.